Advertisement

Psychotropic Medication Side Effects in School-Aged Populations

  • Thomas KubiszynEmail author
  • Sarah S. Mire
  • Allison Meinert
Chapter
Part of the Pediatric School Psychology book series (PSP)

Abstract

The purpose of this chapter is to help inform risk-benefit analysis, treatment decision-making, and monitoring for unwanted outcomes when school-aged children are treated with psychotropic medication. This chapter reviews drugs with pediatric indications (i.e., those approved by the FDA for specific conditions and age ranges) that are currently marketed in the US and prescribed for pediatric emotional and behavioral disorders (EBDs). They include four drug classes and are presented in order of frequency of use within pediatric populations (i.e., 18 years and younger): ADHD drugs (stimulant and non-stimulant), antidepressants (ADs), second-generation antipsychotics (SGAs), and the antiepileptic drugs (AEDs) and lithium. Most of the drugs reviewed have indications for a variety of pediatric EBDs, but the AEDs are only FDA-approved for a medical condition (i.e., pediatric epilepsy). To help guide the thought processes that undergird risk-benefit analysis, a framework for stakeholder’s (e.g., prescribers, parents, school professionals) communications is provided. A set of references and web-based materials are provided to readers for additional information.

Keywords

Side effects Risk-benefit analysis Psychopharmacology Psychosocial interventions ADHD drugs Antidepressants Antipsychotics Antiepileptic drugs Lithium 

References

  1. Advokat, C. D., Comaty, J. E., & Julien, R. M. (2014). A primer of drug action (13th ed.). New York, NY: Worth.Google Scholar
  2. American Academy of Child and Adolescent Psychiatry. (2015). Recommendations about the use of psychotropic medications for children and adolescents involved in child-serving systems. Retrieved from https://www.aacap.org/App_Themes/AACAP/docs/clinical_practice_center/systems_of_care/AACAP_Psychotropic_Medication_Recommendations_2015_FINAL.pdf.
  3. Barkley, R. A. (Ed.). (1998). Attention-deficit hyperactivity disorder. In A handbook for diagnosis and treatment (2nd ed.). New York: Guilford.Google Scholar
  4. Carlson, J. S., & Shahidullah, J. D. (2014). Best practices in assessing the effects of psychotropic medications on student performance. In P. L. Harrison & A. Thomas (Eds.), Best practices in school psychology: Systems-level services (pp. 361–374). Bethesda, MD: National Association of School Psychologists.Google Scholar
  5. Greenhill, L., Kollins, S., Abikoff, H., McCracken, J., Riddle, M., Swanson, J., … Skrobala, A. (2006). Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 1284–1293.CrossRefGoogle Scholar
  6. Hampton, L., Duabresse, M., Chang, H., Alexander, G., & Budnitz, D. (2015). Emergency department visits by children and adolescent for antipsychotic drug adverse events. JAMA Psychiatry, 72, 292–294.CrossRefGoogle Scholar
  7. Hazell, P., & Mirzaie, M. (2013). Tricyclic drugs for depression in children and adolescents. Cochrane Database Systematic Reviews, 18, CD002317.  https://doi.org/10.1002/14651858.cd002317.pub2.
  8. Kubiszyn, T., & Mire, S. S. (2014). Recent FDA drug safety communications for pediatric psychotropics. Journal of Child and Family Studies, 23, 716–727.CrossRefGoogle Scholar
  9. Kubiszyn, T., Mire, S., Dutt, S., Papathopoulos, K., & Backsheider-Burridge, A. (2012). Significant differences in pediatric psychotropic sides effects: Implications for school behavior and performance. School Psychology Quarterly, 27, 4–28.CrossRefGoogle Scholar
  10. Maayan, L., & Correll, C. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 517–535.CrossRefGoogle Scholar
  11. Ninan, A., Stewart, S. L., Theall, L., King, G., Evans, R., Baiden, P., & Brown, A. (2014). Psychotropic medication monitoring checklists: Use and utility for children in residential care. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 23, 38–47.Google Scholar
  12. Noel, C. (2015). Antidepressants and suicidality: History, the black-box warning, consequences, and current evidence. Mental Health Clinician, 5, 202–211.CrossRefGoogle Scholar
  13. Olfson, M., King, M., & Schoenbaum, M. (2015). Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry, 72, 867–874.CrossRefGoogle Scholar
  14. Olfson, M., Marcus, S. C., Weissman, M. M., & Jensen, P. S. (2002). National trends in the use of psychotropic medications in children. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 514–521.CrossRefGoogle Scholar
  15. Pisano, S., Catone, G., Lanzaro, V., Pozzi, M., Clementi, E., Iuliano, R., … Masi, G. (2016). Update on the safety of second generation antipsychotics in youths: A call for collaboration among paediatricians and child psychiatrists. Italian Journal of Pediatrics, 42.  https://doi.org/10.1186/s13052-016-0259-2.
  16. Rapoport, J. (2013). Pediatric psychopharmacology: Too much or too little? World Psychiatry, 12, 118–123.CrossRefGoogle Scholar
  17. Sirven, J. I., Noe, K., Hoerth, M., & Drazkowski, J. (2012). Antiepileptic drugs 2012: Recent advances and trends. Mayo Clinic Proceedings, 87, 879–889.CrossRefGoogle Scholar
  18. Tran, A. R., Zito, J. M., Safer, D. J., & Hundley, S. D. (2012). National trends in pediatric use of anticonvulsants. Psychiatric Services, 63, 1095–1101.CrossRefGoogle Scholar
  19. United States Food and Drug Administration. (2016). Think it through: A guide to managing the risks and benefits of medicines. Retrieved from https://www.fda.gov/Drugs/ResourcesForYou/ucm079492.htm.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Thomas Kubiszyn
    • 1
    Email author
  • Sarah S. Mire
    • 1
  • Allison Meinert
    • 1
  1. 1.University of HoustonHoustonUSA

Personalised recommendations